Clinical Trials Browser

Turcot syndrome, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Melanoma, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Microsatellite Instability, Small Cell Lung Carcinoma

NCT06211036 2025-12-17

DeLLphi-305

Phase 3 Active not recruiting

563 enrolled

Thoracic

Small Cell Lung Carcinoma

NCT04745689 2025-12-10

TAZMAN

Phase 2 Active not recruiting

31 enrolled 15 charts

Thoracic

Small Cell Lung Carcinoma

NCT03703297 2025-11-21

ADRIATIC

Phase 3 Active not recruiting

730 enrolled 19 charts 3 FDA

Thoracic

Carcinoma, Lung Neoplasms, Small Cell Lung Carcinoma

NCT03043872 2025-10-21

CASPIAN

Phase 3 Active not recruiting

987 enrolled 42 charts 3 FDA

Thoracic

Small Cell Lung Carcinoma

NCT06826677 2025-06-24

ARAL

Completed

71 enrolled

Thoracic

Small Cell Lung Carcinoma

NCT04774380 2025-05-23

LUMINANCE

Phase 3 Completed

152 enrolled 17 charts

Thoracic

Small Cell Lung Carcinoma

NCT04870112 2025-04-17

SCope-D1

Phase 1 Terminated

18 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma

NCT03509012 2025-01-14

CLOVER

Phase 1 Completed

105 enrolled

Head & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma

NCT04504669 2024-11-05

First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours

Phase 1 Completed

60 enrolled

BreastDermatologicGenitourinaryGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Melanoma, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT02658214 2020-08-20

Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors

Phase 1 Completed

32 enrolled

BreastGastrointestinalGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Peritoneal Neoplasms, Stomach Neoplasms, Carcinoma, Pancreatic Ductal, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT03544723 2020-06-09

Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.

Phase 2 Unknown

40 enrolled

BreastDermatologicGastrointestinalGenitourinaryGynecologicLymphoidThoracic

Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Hodgkin Disease, Liver Neoplasms, Lymphoma, Melanoma, Stomach Neoplasms, Carcinoma, Merkel Cell, Neoplasms, Squamous Cell, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

Clinical Trials

IMFINZI-subQ

DeLLphi-312

DeLLphi-313

MK-6070-002

ALBORAN

A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC

ARSENAL

(DeLLphi-310)

MEDIOLA

A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer

QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors

DeLLphi-305

TAZMAN

ADRIATIC

CASPIAN

ARAL

LUMINANCE

SCope-D1

CLOVER

First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours

Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors

Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.